These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37517117)

  • 1. Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study.
    Chen J; Xu C; Wang Q; Lv J; Lu W; Zhang Y; Yao Y; Gu X; Wu G; Hao Y; Pan W; Wang W; Zhang S; Lv T; Song Y; Wang D
    Lung Cancer; 2023 Sep; 183():107315. PubMed ID: 37517117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.
    Qin H; Yan H; Chen Y; Xu Q; Huang Z; Jiang W; Wang Z; Deng L; Zhang X; Zhang L; Yang N; Zeng L; Zhang Y
    BMC Cancer; 2024 Aug; 24(1):952. PubMed ID: 39097705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
    Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
    Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
    Zhao Y; He Y; Wang W; Cai Q; Ge F; Chen Z; Zheng J; Zhang Y; Deng H; Chen Y; Lao S; Liang H; Liang W; He J
    Lancet Oncol; 2024 Aug; ():. PubMed ID: 39159630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
    Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
    Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer.
    Mi J; Huang Z; Zhang R; Zeng L; Xu Q; Yang H; Lizaso A; Tong F; Dong X; Yang N; Zhang Y
    ESMO Open; 2022 Feb; 7(1):100347. PubMed ID: 34953403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
    Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
    Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials.
    Wang K; Fu Z; Sun G; Ran Y; Lv N; Wang E; Ding H
    BMC Immunol; 2024 Jun; 25(1):37. PubMed ID: 38937711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Zhao L; Zhao Z; Yan X; Wu F; Sun N; Guo R; Yu S; Hu X; Feng J
    Int J Clin Pract; 2024; 2024():8585035. PubMed ID: 38375028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.
    Li Y; Wang Y; Niu K; Chen X; Xia L; Lu D; Kong R; Chen Z; Duan Y; Sun J
    Oncotarget; 2016 Oct; 7(43):70535-70545. PubMed ID: 27655708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure.
    Li X; Huang H; Sun Y; Jiang Q; Yu Y
    Front Oncol; 2023; 13():1265236. PubMed ID: 37869096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
    Yang G; Xu H; Yang L; Xu F; Zhang S; Yang Y; Wang Y
    Lung Cancer; 2020 Sep; 147():229-236. PubMed ID: 32739743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
    Wang Q; Gao W; Gao F; Jin S; Qu T; Lin F; Zhang C; Zhang J; Zhang Z; Chen L; Guo R
    BMC Cancer; 2021 May; 21(1):602. PubMed ID: 34034713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies.
    Gao RL; Song J; Sun L; Wu ZX; Yi XF; Zhang SL; Huang LT; Ma JT; Han CB
    Front Pharmacol; 2022; 13():920165. PubMed ID: 36034821
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.